- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: Hyperphenylalaninemia.
Displaying page 1 of 1.
| EudraCT Number: 2006-000648-15 | Sponsor Protocol Number: BH4/III/05/001 | Start Date*: 2006-06-08 | |||||||||||
| Sponsor Name:ORPHANETICS Pharma Entwicklungs- GmbH | |||||||||||||
| Full Title: A double-blind, placebo-controlled, multicentre study with an open-label extension to evaluate the efficacy and safety of tetrahydrobiopterin (BH4) in children and adolescents with hyperphenylalani... | |||||||||||||
| Medical condition: Hyperphenylalaninemia due to phenylalanine hydroxylase deficiency. Phenotypes: classic phenylketonuria (PKU), mild PKU (MPK) or mild hyperphenylalaninemia (HPA). | |||||||||||||
|
|||||||||||||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-001650-15 | Sponsor Protocol Number: EMR700773-510 | Start Date*: 2015-06-26 |
| Sponsor Name:Merck Serono Middle East FZ-LLC | ||
| Full Title: A Phase III Non-comparative Open-label Clinical Study to Evaluate the Response to and Safety of Kuvan (Sapropterin Dihydrochloride) After 6 Weeks of Treatment in Patients of 4 to 18 Years of Age Wi... | ||
| Medical condition: Phenylketonuria | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2004-002071-16 | Sponsor Protocol Number: PKU-001 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:BioMarin Pharmaceutical Inc. | |||||||||||||
| Full Title: A Phase 2, Multicenter, Open-Label Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin Treatment in Subjects with Phenylketonuria Who Have Elevated Phenylalanine Levels | |||||||||||||
| Medical condition: Phenylketonuria (PKU) | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Completed) DE (Completed) GB (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-012978-12 | Sponsor Protocol Number: ME026 | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||
| Sponsor Name:Merck Serono, an affiliate of E. Merck AB | ||||||||||||||||||||||||||||
| Full Title: A Phase IV, prospective, open-label, uncontrolled, single-centre cohort trial to be conducted in Norway to assess the responsiveness of subjects with phenylketonuria (PKU) to treatment with KuvanĀ® ... | ||||||||||||||||||||||||||||
| Medical condition: Hyperphenylalaninemia (HPA) in adults and children >=16 years of age with phenylketonuri (PKU) (classic or mild PKU, or mild hyperphenylalaninemia (HPA)). | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: NO (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2005-003778-13 | Sponsor Protocol Number: PKU-007 | Start Date*: 2006-07-13 | |||||||||||
| Sponsor Name:BioMarin Pharmaceutical Inc | |||||||||||||
| Full Title: A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Phenoptin in Subjects with Hyperphenylalaninemia Due to Primary BH4 Deficiency | |||||||||||||
| Medical condition: Phenylketonuria (PKU) | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-000474-29 | Sponsor Protocol Number: PTC923-MD-003-PKU | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:PTC Therapeutics, Inc. | |||||||||||||
| Full Title: A Phase 3 Study of PTC923 in Subjects with Phenylketonuria | |||||||||||||
| Medical condition: Metabolic Disorders - Phenylketonuria | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Ongoing) PT (Completed) DK (Completed) NL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-003777-24 | Sponsor Protocol Number: PKU-006 | Start Date*: 2006-03-24 | |||||||||||
| Sponsor Name:BioMarin Pharmaceutical Inc. | |||||||||||||
| Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Phenoptin 20 mg/kg/day to Increase Phenylalanine Tolerance in Phenylketonuric Child... | |||||||||||||
| Medical condition: Phenylketonuria (PKU) | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Completed) GB (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-015844-41 | Sponsor Protocol Number: BMN162-502 | Start Date*: 2013-07-25 | |||||||||||
| Sponsor Name:BioMarin International Ltd. | |||||||||||||
| Full Title: A Phase IV Open-Label, Single-Cohort Study of the Long-Term Neurocognitive Outcomes in 4 to 5 Year-Old Children with Phenylketonuria Treated with Sapropterin Dihydrochloride (KuvanĀ®) for 7 Years. | |||||||||||||
| Medical condition: Phenylketonuria | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-000497-28 | Sponsor Protocol Number: PTC923-MD-004-PKU | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:PTC Therapeutics, Inc. | |||||||||||||
| Full Title: Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria | |||||||||||||
| Medical condition: Metabolic Disorders - Phenylketonuria | |||||||||||||
|
|||||||||||||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.